Where Private Equity Is Finding Value In MedTech

MedTech investment trends: Part 1 (Read Part 2, “Where MedTech is attracting PE attention with less FDA burden.”)

Overview

MedTech’s reset is creating openings for private equity, but disciplined diligence will separate opportunity from risk.

Private equity is putting more money into MedTech, but that capital is concentrating around fewer, bigger deals in faster-growing categories.

In the first half of 2026, MedTech mergers and acquisitions (M&A) value was roughly 160% higher than the same period in 2025, while the number of deals increased just 5%. Average deal value more than doubled, from slightly less than $1 billion to approximately $2.1 billion, according to EY and Capital IQ data.